Krankenhaus Jerusalem

Recent papers from Krankenhaus Jerusalem

1. Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancerESMO Open · 2026
2. Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP InhibitorsJAMA Oncology · 2026
3. Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyJCO Precision Oncology · 2026
4. 78P Desmocollin 2 as a predictive marker for the development of distant metastasis (mets) in Breast Cancer (BC)ESMO Open · 2026
5. Circulating microRNA Profiles as Diagnostic Tools for High-Grade Cervical Lesions and HPV Genotype StratificationCells · 2026
6. Evidenz‐ und konsensbasierte (S3) Leitlinie: Lichen sclerosusJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026
7. ABC8 Consensus: Assessment by a German Group of ExpertsBreast Care · 2026
8. Abstract PS4-08-07: Predicting response and survival after neoadjuvant systemic treatment with on-treatment biopsiesClinical Cancer Research · 2026
9. Abstract RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) - a Pooled Analysis from nine Neoadjuvant GBG/AGO-B TrialsClinical Cancer Research · 2026
10. Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-EBMC Cancer · 2025
11. Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 TrialClinical Cancer Research · 2025
12. Myocardial Strain Measurements Obtained with Fast-Strain-Encoded Cardiac Magnetic Resonance for the Risk Prediction and Early Detection of Chemotherapy-Related Cardiotoxicity Compared to Left Ventricular Ejection FractionDiagnostics · 2025
13. Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).ESMO Open · 2025
14. Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trialsAnnals of Oncology · 2025
15. Anogenital high-risk HPV prevalence and screening considerations in female transplant recipients: a cross-sectional studyBMC Women s Health · 2025
16. 189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trialESMO Open · 2025
17. Update vulval dermatology – diagnostics and therapyJDDG Journal der Deutschen Dermatologischen Gesellschaft · 2024
18. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancerCell Reports Medicine · 2024
19. Systematic review – Adjuvant radiotherapy of the vulva in primary vulvar cancerGynecologic Oncology · 2024
20. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical TrialsClinical Cancer Research · 2024